Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
- Authors
- Hyun, Soonsil; Shin, Dongyun
- Issue Date
- Nov-2021
- Publisher
- MDPI
- Keywords
- Drug resistance; KRAS inhibitors; KRAS mutant; PROTAC; RAS; Targeted protein degradation (TPD)
- Citation
- International Journal of Molecular Sciences, v.22, no.22
- Journal Title
- International Journal of Molecular Sciences
- Volume
- 22
- Number
- 22
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82838
- DOI
- 10.3390/ijms222212142
- ISSN
- 1661-6596
- Abstract
- Drug resistance continues to be a major problem associated with cancer treatment. One of the primary causes of anticancer drug resistance is the frequently mutated RAS gene. In particular, considerable efforts have been made to treat KRAS-induced cancers by directly and indirectly controlling the activity of KRAS. However, the RAS protein is still one of the most prominent targets for drugs in cancer treatment. Recently, novel targeted protein degradation (TPD) strategies, such as proteolysis-targeting chimeras, have been developed to render “undruggable” targets druggable and overcome drug resistance and mutation problems. In this study, we discuss small-molecule inhibitors, TPD-based small-molecule chemicals for targeting RAS pathway proteins, and their potential applications for treating KRAS-mutant cancers. Novel TPD strategies are expected to serve as promising therapeutic methods for treating tumor patients with KRAS mutations. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82838)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.